Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia.
Arlene ChanChristopher LommaHuiJun ChihElizabeth BlackelyNatasha WoodwardDaphne TsoiKerry CheongMitchell ChipmanAndrew RedfernPublished in: Asia-Pacific journal of clinical oncology (2021)
Similar efficacy was demonstrated for eribulin when given in the first-line to beyond the fifth line of chemotherapy in all subtypes of MBC.